EI
CGON icon

EAM Investors’s CG Oncology CGON Stock Holding History

EAM Investors’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.12M Buy
+46,102
New +$2.61M 0.36% 135

Other funds holding CGON

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

EAM Investors's CGON Position: Q1 2026 in Review

EAM Investors opened a new position in CG Oncology (CGON) in Q1 2026: 46,102 shares worth $3.12M. The stake represents 0.36% of the portfolio and ranks #135 among its holdings.

233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • EAM Investors held 46,102 shares of CG Oncology worth $3.12M as of Q1 2026.
  • CG Oncology was a new EAM Investors position in Q1 2026.
  • CG Oncology made up 0.36% of EAM Investors's portfolio in Q1 2026, its #135 holding.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.